source
- FDA advisory panel adds six peptides to compounding bulk drug list, rejects oneThe FDA’s advisory committee concluded a two-day meeting on Friday, reviewing seven peptide drug substances for inclusion on the agency’s bulk-drug compounding list. Committee members voted to add…
- Ipsen's Bylvay fails Phase 3 trial in children with biliary atresiaIpsen announced that its experimental therapy Bylvay did not meet its primary endpoint in a Phase 3 trial targeting biliary atresia in infants. Biliary atresia is a rare pediatric liver disorder i…